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Abstract 
BACKGROUND: Drug resistance to malaria is still a problem in various regions, and there have even been 
developments in resistance to the ACTs (artemisinin-based combination therapies) as standard antimalarial drugs 
included to artemisinin’s partner drugs. Ethyl acetate fraction of G. mangostana L rind, containing xanthones as 
an antioxidant, has antimalarial activity in vitro which has a synergistic effect with artemisinin. That’s why the 
activities of this fraction are needed to be studied in vivo.  
AIM: To explore the antimalarial and antioxidant activity of ethyl acetate fraction of Garcinia mangostana L rind in 
mice.  
METHODS: This was a complete randomised design true experimental study. Six groups of mice: a healthy mice 
group and 5 groups of Plasmodium berghei inoculated mice treated with various doses of the sample for 3 days 
compared to artemisinin. Parasitemia and total antioxidant status were examined and analysed using ANOVA, 
and probit analysis were done. 
RESULTS: The parasitemia level in all of the treatment groups were lower than the positive control group without 
treatment (p < 0.01) and the parasitemia level was the lowest in artemisinin group which was not significantly 
different from the 100 mg/kg body weight dose group (p > 0.05). The parasitemia level in 20 and 4 mg/kg body 
weight dose groups were higher than the artemisinin group (p < 0.01). Parasite growth inhibition rate from the 
highest to the lowest consecutively was: artemisinin, 100 mg/kg body weight, 20 mg/kg body weight, 4 mg/kg 
body weight, and positive control group (p < 0.05) and ED50 was 3.396 mg/kg body weight. Total antioxidant 
status was the highest in 20 mg/ kg body weight dose and higher than the negative control group (p < 0.05) while 
the lowest total antioxidant status was in the positive control group.  
CONCLUSION: Ethyl acetate fraction of G. mangostana L rind potentially showed antimalarial and antioxidant 
activity in vivo. Further study is needed to explore the detail of its mechanism of action and its quantitative 
phytochemical analysis to find the leading compound in it. 
 
 
Introduction 
 
The main issue of malaria is the number of 
cases that are resistant to conventional antimalarial 
drugs. To overcome this issue, artemisinin-based 
combination regimen has been used. But resistance 
to the available artemisinin-based combination drugs 
has been reported in some countries [1]. Resistance 
also happens against artemisinin partner drugs such 
as piperaquine in dihydroartemisinin-piperaquine 
regimen in Cambodia [2], also against lumefantrine in 
artemether-lumefantrine regimen [3]. Therefore, it is 
necessary to find other alternative reserved drugs that 
could potentially be paired with artemisinin. Part of the 
mangosteen (G. mangostana L) fruit, i.e. the rind, 
contains xanthones [4]. A synthetic xanthone, i.e. 2,3, 
4,5,6-pentahydroxy xanthone prevent hemozoin 
formation by inhibiting heme polymerization [5]. 
Xanthones are also antioxidant and are possibly 
suitable for use in malaria because malaria decreases 
levels of antioxidant [6].
 
In vitro, it has been proven 
that some xanthone compounds worked 
synergistically with artemisinin as antimalaria against 
a 3D7 clone of Plasmodium falciparum [7].
 
The 
previous study showed that ethanolic extract and 
ethylacetate fraction of G. mangostana L rind had 
antimalarial activity and worked synergistically with 
artemisinin against a 3D7 clone of P. falciparum in 
vitro [8]. In the previous study, in vivo antimalarial 
effect of ethanolic extract of the G. mangostana L rind 
also has been studied against P. berghei inoculated 
mice [9]
 
but there is no report about the antimalarial 
activity of the ethyl acetate fraction in vivo. By the 
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way, reported by other researchers that 
alphamangostin, which is an antioxidant, containing in 
this preparation caused this fraction to have SPF [10].
 
This fact supports the background of this study to 
explore the antioxidant activity besides the 
antimalarial activity of the G. mangostana L rind 
ethylacetate fraction in vivo in P. berghei inoculated 
mice.  
   
 
Material and Methods  
 
Ethical Issue  
This study was approved by the ethics 
committee of Maranatha Christian University-Hospital 
Immanuel according to SK NO: 040/KEP/IV/2014 on 
the principle of 3 R (reduction, replacement, 
refinement).  
  
Plant Sample  
Mangosteen fruit was collected from Subang, 
West Java, Indonesia in March 2012, and has been 
identified by Djuandi, a curator at the Herbarium 
Bandungense, Sekolah Tinggi Imu Hayati, Bandung 
Institute of Technology (ITB), Bandung, Indonesia. 
The fruit was ripe with dark purple colour. The 
voucher specimen has been deposited by Dr J S 
Rahajoe in a publicly available herbarium, the 
Herbarium Bogoriense, Research Center of Biology, 
Indonesian Institute of Sciences in 2012 with 
deposition number of 1143/IPH.1.02/lf.8/VII/2012. 
After fruit washing, the rind has been proximately 
analysed previously [8]. 
 
G. mangostana L Rind extraction, 
 fractionation, and treatment preparation  
The rind was cut into small pieces, air dried, 
pulverised and macerated with 96% alcohol, followed 
by evaporation to obtain paste like extract according 
to the standard procedure [11]. The extract was 
macerated again with hexane and ethyl acetate 
consecutively using the same method to obtain paste 
like ethyl acetate fraction from the hexane fraction. 
This fraction was stored in -20°C freezer until used. 
For this study, the artemisinin, as well as this fraction, 
were dissolved in dimethyl sulfoxide (DMSO, Sigma 
Aldrich, IL, USA) to make a stock solution. Ethyl 
acetate fraction stock solution was diluted to adjust 
each of the treatment doses in 0.1 mL solution. The 
doses were 100 mg/kg body weight, 20 mg/kg body 
weight, and 4 mg/kg body weight daily. Artemisinin 
dose as a positive control dose was 50 mg/kg body 
weight/day in 0.1 mL.  
 
Animals and treatment  
A group of 24 DDY strain male mice, 8 weeks 
of age with 20-25 grams weight, were obtained from 
the Biopharma Institute, Bandung. They were divided 
into 6 treatment groups randomly in complete 
randomised design consisting of 5 groups of P. 
berghei inoculated, and 1 group of healthy non 
inoculated mice as a negative control group (NC). 
Each group contained 4 replications according to a 
certain formula from Hanafiah [12]. The mice were fed 
with pellets and water ad libitum. The P. berghei was 
obtained from the Malaria Laboratory, The Eijkman 
Insitute for Molecular Biology, Jakarta and was 
inoculated intraperitoneally into a donor mouse until 
the minimal parasitemia of 5-10%, and then this 
mouse was terminated by cervical dislocation, and 
cardiac puncture was done to obtain the parasites. All 
of the 24 experimental mice were adapted to the 
condition of biology laboratory for 1 week in condition: 
12 hours light/ dark cycle, 23-24°C, 60-70% relative 
humidity, then each of the 20 mice of the 5 inoculated 
groups were inoculated intraperitoneally with 10
7 
parasitized red blood cells (pRBC) from the donor in 
200 µL PBS solution. After reaching about 5% 
parasitaemia, around the 4-5
th
 day, these mice were 
divided into five groups.  
Each of these groups was orally treated every 
day, once daily, for 3 days consecutively as follows: 
aquadest (the positive control group = PC), 50 mg/kg 
body weight/day of artemisinin (artemisinin control 
group = AC), 100 mg/kg body weight/day of ethyl 
acetate fraction (the first dose group = A1), 20 mg/kg 
body weight/ day of ethyl acetate fraction (second 
dose group = A2), and 4 mg/kg body weight/day of 
ethyl acetate fraction (third dose group = A3). 
Parasitaemia was calculated before and after the 
treatment on the fourth day by determining the 
parasites amount microscopically per 5,000 red blood 
cells in Giemsa stain thin blood smears. The rest 4 
healthy non inoculated mice were used as a negative 
control (NC) for the antioxidant test. After completion 
of the experiment, all of these mice in six groups were 
terminated by neck dislocation, and their blood was 
taken from cardiac puncture for total antioxidant levels 
examination (total antioxidant status = TAS).  
 
Total antioxidant status analysis  
Each of the mice serum samples was 
analysed to determine total antioxidant status using 
Cayman Antioxidant Assay Kit accordingly. The 
absorbances were read at 750 nM by ELISA plate 
reader.  
  
Statistical analysis  
The data of parasitaemia and total antioxidant 
status were analysed using ANOVA followed by 
Tukey HSD (α = 0.05) and ED50 (effective dose 50) of 
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the fraction as antimalaria was analyzed using probit 
analysis.  
 
 
Results 
 
The effect of the ethyl acetate fraction of 
 G. mangostana L Rind against 
 parasitaemia in mice suffering berghei 
 malaria 
 The parasitemia level in the 5 treatment 
groups on the day before treatment, day 4 (after 3 
days treatment), and parasite growth inhibition is 
shown in following Table 1. 
Table 1: Parasitemia level in percentage in the 5 treatment 
groups on the day before treatment, day 4 (after 3 days of 
treatment), and parasite growth inhibition 
Treatment 
Groups 
Parasitemia level average 
± stdev (%) before 
treatment 
Parasitemia level average 
± stdev (%) on day 4 (after 
3 days of treatment) 
Parasite growth 
inhibition average 
±stdev (%) 
PC  (5.22 ± 0.5)
a
 (15.9 ± 3.34)
a
  
AC  (5.32 ± 1.8)
a
 (0.24 ± 0.11)
b
 98 ± 0.01
a
 
A1  (5.42 ± 1.2)
a
 (3.02 ± 0.33)
b
 81 ± 0.02
b
 
A2  (5.3 ± 0.93)
a
 (6.1 ± 0.75)
c
 62 ± 0.05
c
 
A3  (5.2 ± 0.98)
a
 (7.3 ± 0.85)
c
 54 ± 0.05
d
 
Notes: the same alphabet superscript in each column shows no significant 
difference (p > 0.05); PC = mice suffering berghei malaria without treatment; AC = mice 
suffering berghei malaria treated with artemisinin 50 mg/kg body weight; A1 = mice 
suffering berghei malaria treated with 100 mg/kg body weight of ethylacetate fraction; A2 = 
mice suffering berghei malaria treated with 20 mg/kg body weight of ethyl acetate fraction; 
A3 = mice suffering berghei malaria treated with 4 mg/kg body weight of ethylacetate 
fraction. 
 
Parasitemia levels of the five groups after 3 
days of treatment (day 4) could be compared because 
each of the parasitemia levels on day 0 was no 
significant difference (p > 0.05). This was shown in the 
data of Figure 1. 
 
Figure 1: Parasitaemia level in percentage in the 5 treatment 
groups after 3 days of treatment (day 4). The same letter above 
each of the columns indicates that there is no significant difference 
(P > 0.05); PC = mice suffering berghei malaria without treatment; 
AC = mice suffering berghei malaria treated with artemisinin 50 
mg/kg body weight; A1 = mice suffering berghei malaria treated with 
100 mg/kg body weight of ethyl acetate fraction; A2 = mice suffering 
berghei malaria treated with 20 mg/kg body weight of ethyl acetate 
fraction; A3 = mice suffering berghei malaria treated with 4 mg/kg 
body weight of ethyl acetate fraction 
Parasite growth inhibition rate after 3 days of 
treatment (day 4) indicates that the highest to the 
lowest group was: AC, A1, A2, and A3 consecutively 
(p < 0.05). This was shown in the following Figure 2.  
 
Figure 2: The parasite growth inhibition rate (%) in various 
treatment. The same letter above each of the columns indicates 
that there is no significant difference (P > 0.05); PC = mice suffering 
berghei malaria without treatment; AC = mice suffering berghei 
malaria treated with artemisinin 50 mg/kg body weight, A1 = mice 
suffering berghei malaria treated with 100 mg/kg body weight of 
ethyl acetate fraction; A2 = mice suffering berghei malaria treated 
with 20 mg/ kg body weight of ethylacetate fraction; A3 = mice 
suffering berghei malaria treated with 4 mg/kg body weight of ethyl 
acetate fraction 
 
As shown in Figure 1, dose 1, dose 2, and 
dose 3 of ethyl acetate fraction of G. mangostana L 
rind showed antimalarial activity (p < 0.05) and dose 1 
was the strongest one which had an equivalent 
antimalarial activity as artemisinin (p > 0.05).  
ED50 (effective dose 50), which indicates the 
level of antimalarial activity could be calculated from 
the parasite growth inhibition data shown in Figure 2 
using probit analysis. The correlation between the log 
of doses and probit of the percentage of parasite 
growth inhibition was shown in Figure 3. 
 
Figure 3: Correlation between the probit of the percentage of 
parasite growth inhibition and the log of doses. According to the 
formula shown in the figure, ED50 was 3.396 mg/kg body weight 
 
 
Effect of the ethyl acetate fraction of G. 
 mangostana L rind against total 
 antioxidant status in mice suffering 
 berghei malaria  
 Total antioxidant status in the sera of mice 
suffering berghei malaria after various treatments are 
shown in the following Table 2.  
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Table 2: Total antioxidant status in the sera of mice suffering 
berghei malaria after various treatments 
 Total antioxidant level (mMTrolox) Average±SD 
PC 0.070 0.067 0.081 0.099 0.079
d 
± 0.015 
NC 0.221 0.222 0.276 0.222 0.235
b
 ± 0.027 
AC 0.193 0.231 0.203 0.191 0.204
b
 ± 0.018 
A1 0.121 0.146 0.112 0.108 0.122
c 
± 0.017 
A2 0.2316 0.2732 0.2393 0.3578 0.276
a 
± 0.058 
A3 0.2046 0.2240 0.2039 0.2288 0.215
b 
± 0.013 
Notes: the different superscript alphabet means that there is a significant difference (p < 
0.05). NC = healthy mice without treatment; PC = mice suffering berghei malaria without 
treatment; AC = mice suffering berghei malaria treated with artemisinin 50 mg/kg body 
weight, A1 = mice suffering berghei malaria treated with 100 mg/kg body weight of ethyl 
acetate fraction; A2 = mice suffering berghei malaria treated with 20 mg/kg body weight of 
ethyl acetate fraction; A3 = mice suffering berghei malaria treated with 4 mg/kg body 
weight of ethyl acetate fraction; SD = standard deviation. The TAS level from the highest to 
the lowest consecutively was: A2, NC/AC/A3, A1, PC. 
 
As shown in Table 2, the TAS level of ethyl 
acetate fraction groups was higher than PC group (p < 
0.05) which meant that the fraction had antioxidant 
activity and could rise the TAS level and possibly 
could encounter the lack of antioxidant status in mice 
suffering malaria. The highest serum antioxidant level 
was in A2 treatment, not in A1. That’s mean that there 
was an optimum dose of this fraction, which leads to 
the maximum level of the serum antioxidant status. 
This was consistent with our previous research on co-
cultivation of 3D7 clone of Plasmodium falciparum- 
HUVEC (human umbilical vein endothelial cell) which 
were incubated with IC50 of artemisinin and various 
concentrations of L ascorbic acid as mentioned in the 
discussion chapter.  
  
 
Discussion 
 
Qualitative phytochemical analysis of ethyl 
acetate fraction of G. mangostana L rind was done 
according to the reported method. It contains several 
phytochemicals: tannins, terpenoids, triterpenoids, 
and flavonoids [13], [14]. 
The antimalarial activity of this ethyl acetate 
fraction of G. mangostana L rind in vivo supports the 
previous study indicating this antimalarial activity in 
vitro [8].
 
Similar in vivo study in Swiss Webster mice 
suffering berghei malaria showed that ethyl acetate 
fraction of G. mangostana L rind also had a very good 
antimalarial activity even more active than hexane or 
methanol fraction [15].
 
This antimalarial action of the 
ethyl acetate fraction of G. mangostana L rind may be 
caused by alphamangostin containing in it [10], and 
alphamangostin itself is a kind of xanthones which 
had good antimalarial action in vitro against 3D7 clone 
of P. falciparum working synergistically with 
artemisinin [7]. Xanthones could inhibit aggregation of 
heme, block hemozoin formation, and they bind to the 
soluble heme cause intra food vacuole osmotic 
pressure enhancement, and the lysis [5]. 
Transmission electron microscopical image also 
showed the inhibition of hemozoin formation of 
alphamangostin [16].
 
The result of this study is closely 
correlated with the qualitative phytochemical analysis, 
which is needed to be followed by quantitative 
analysis in further study. This antimalarial action of 
ethyl acetate fraction of G. mangostana L rind was 
supported the fact that besides gammamangostin, 
alphamangostin was the most abundant kind of 
xanthones in mangosteen rind [17].  
According to P. falciparum foot printing study, 
mangosteen rind extract targeted several metabolic 
pathways, particularly glucose and TCA metabolisms 
[18]. 
According to Figure 3 and the ED50 of this 
ethyl acetate fraction against P. berghei in vivo, the 
fraction has potentially a very good antimalarial 
activity [19].
 
Further study is needed to observe this 
activity for a longer period for detecting the possibility 
of recrudescence. Treatment with higher dose is also 
needed to find out the dose that can inhibit 100% 
parasite growth. 
The previous research indicated that L 
ascorbic acid as an antioxidant could improve the 
viability of HUVEC and produce the highest level of 
GSH at optimum supplementation and not at the 
maximum [20]. Another study also showed the similar 
result about the antioxidant as well as prooxidant 
effect of curcumin which was concentration dependent 
that’s mean in low concentration it had antioxidant 
effect in contrast against high concentration which had 
pro-oxidant effect [21]. This phenomenon is very 
interesting to be studied further. 
In conclusion, ethylacetate fraction of G. 
mangostana L rind potentially showed antimalarial 
and antioxidant activity in vivo. Further study is 
needed to explore the detail of its mechanism of 
action and its quantitative phytochemical analysis to 
find the leading compound in it. Longer period of 
parasitaemia observation and higher doses are also 
needed to detect recrudescence possibility and to 
explore the dose which can cause 100% inhibition of 
parasite growth. 
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